Segment reporting (Tables)

9 Months Ended

May 31, 2023

Segment Reporting [Abstract]

Reconciliation of Operating Income (Loss) from Segments to Consolidated

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Three months ended May 31,				Nine months ended May 31,
	2023		2022		2023		2022
Sales:
U.S. Retail Pharmacy	$	27,866	$	26,695	$	82,648	$	82,394
International	5,573		5,305		16,414		16,686
U.S. Healthcare	1,975		596		4,597		1,173
Corporate and Other 1	—		1		—		—
Walgreens Boots Alliance, Inc.	$	35,415	$	32,597	$	103,659	$	100,254
Adjusted operating income (Non-GAAP measure):
U.S. Retail Pharmacy	$	962	$	966	$	3,134	$	4,243
International	208		174		676		563
U.S. Healthcare	(172)		(129)		(483)		(218)
Corporate and Other	(39)		(56)		(139)		(198)
Walgreens Boots Alliance, Inc.	$	959	$	955	$	3,188	$	4,389

1.Includes certain eliminations.

The following table reconciles adjusted operating income to operating (loss) income (in millions):

	Three months ended May 31,				Nine months ended May 31,
	2023		2022		2023		2022
Adjusted operating income (Non-GAAP measure)	$	959	$	955	$	3,188	$	4,389
Certain legal and regulatory accruals and settlements	(268)		(734)		(7,249)		(734)
Acquisition-related amortization	(274)		(201)		(851)		(616)
Acquisition-related costs	(70)		(40)		(257)		(155)
Transformational cost management	(414)		(185)		(697)		(458)
Adjustments to equity earnings in AmerisourceBergen	(61)		(60)		(178)		(155)
LIFO provision	(51)		(55)		(89)		(64)
Impairment of intangible assets	(299)		—		(299)		—
Operating (loss) income (GAAP measure)	$	(477)	$	(320)	$	(6,431)	$	2,209